Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
Immatics Initiated at Overweight by Piper Sandler
Immatics Analyst Ratings
Piper Sandler Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $19
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Remains a Buy on Immatics (IMTX)
Immatics Analyst Ratings
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Buy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside Potential
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed on Immatics' Promising Pipeline and Upcoming Data Catalysts
Mizuho Bank: Maintaining the Immatics (IMTX.US) rating, adjusted from buy to buy rating, and adjusted the target price from $14.00 to $16.00.
Immatics Analyst Ratings
Mizuho Maintains Buy on Immatics, Raises Price Target to $16
Buy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising Outlook
Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships
Positive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh's Recommendation